STAAR Surgical (NASDAQ:STAA – Get Free Report) has been assigned an average recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $46.43.
Several research firms have recently commented on STAA. Mizuho increased their target price on STAAR Surgical from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th. Piper Sandler raised their price objective on shares of STAAR Surgical from $33.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, May 8th. BTIG Research upped their target price on shares of STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Morgan Stanley cut shares of STAAR Surgical from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $50.00 to $37.00 in a research report on Monday, July 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, August 8th.
Read Our Latest Stock Analysis on STAA
Institutional Inflows and Outflows
STAAR Surgical Price Performance
Shares of STAA stock opened at $36.43 on Friday. The company’s fifty day moving average price is $41.62 and its two-hundred day moving average price is $40.01. The firm has a market capitalization of $1.79 billion, a P/E ratio of 117.52 and a beta of 0.59. STAAR Surgical has a 12 month low of $26.66 and a 12 month high of $52.68.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.09). STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. The business had revenue of $99.01 million during the quarter, compared to analyst estimates of $95.22 million. During the same quarter last year, the firm posted $0.23 EPS. The company’s revenue was up 7.3% compared to the same quarter last year. On average, sell-side analysts anticipate that STAAR Surgical will post 0.08 EPS for the current year.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Articles
- Five stocks we like better than STAAR Surgical
- What is a buyback in stocks? A comprehensive guide for investors
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What Are Dividends? Buy the Best Dividend Stocks
- Jeff Brown’s Exegesis AI Stock Picks
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.